Bridge to Life™ Unveils Critical Findings on HOPE at WTC 2025
In an exciting development for the field of organ transplantation, Bridge to Life™ Ltd. has announced the presentation of significant clinical data on hypothermic oxygenated perfusion (HOPE) during the World Transplant Congress (WTC) 2025 in San Francisco, happening from August 2 to August 6. Recognized as a global leader in organ preservation and perfusion technology, Bridge to Life's presentation focuses on the findings of the Bridge to HOPE trial, emphasizing both clinical and economic facets of liver transplantation.
Essential Results from the Bridge to HOPE Trial
The Bridge to HOPE trial represents a pivotal study that evaluated the effects of hypothermic oxygenated perfusion on liver transplants. During the congress, key results from the 12-month follow-up will be shared, demonstrating how HOPE significantly impacts not only the viability of liver transplants but also their economic implications. The data will be highlighted in various oral presentations, including a plenary session that underscores the advances in transplant science fostered by Bridge to Life.
Plenary Session Details
One of the standout moments at the congress will be the plenary session scheduled for August 4 at 10:30 AM, presented by Dr. Chase J. Wehrle from the Cleveland Clinic. This discussion will center around a comparative analysis of hypothermic-oxygenated and normothermic machine perfusion, delving into the details from the randomized trial alongside institutional outcomes observed prospectively.
Poster Presentations and Abstracts
In addition to the plenary session, Bridge to Life will also feature several poster presentations throughout the congress:
- - Impact of Hypothermic Oxygenated Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation, presented by Dr. Marco Maria Pascale on August 4.
- - Mitochondrial Injury and Function, comparing preservation methods, presented by Dr. Omer Faruk Karakaya on August 5.
- - Economic Assessment of Hypothermic Oxygenated Machine Perfusion will showcase the economic viability associated with HOPE, presented by Dr. David Axelrod later that day.
Moreover,
late-breaking oral abstracts will offer further insights into innovative approaches for assessing viability in split liver grafts, a crucial topic presented by Dr. Geofia Crasta.
Symposium on HOPE
In line with these advancements, Bridge to Life™ will sponsor a symposium on August 4 from 7:00 AM to 8:00 AM PDT titled, "Hypothermic Oxygenated Perfusion (HOPE): From Science to Clinical Impact." This session aims to bridge the gap between innovative research and its real-world applications in transplantation.
Moderated by Dr. Garret Roll from the University of California San Francisco, the symposium will feature leaders such as Dr. David Axelrod and Dr. Andrea Schlegel discussing the implications of HOPE across various settings.
About Bridge to Life™ Ltd
Bridge to Life™ Ltd. is a recognized player in the organ preservation domain, providing superior solutions like Belzer UW®, EasiSlush®, and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. The company is committed to enhancing product quality, innovation, and accessibility, partnering with top Transplant Centers and Organ Procurement Organizations worldwide. While VitaSmart™ is currently available in several markets globally, it is still pending FDA approval in the United States.
Overall, WTC 2025 will serve as a prominent platform for Bridge to Life™ to share significant advancements that have the potential to reshape the landscape of liver transplantation and improve patient outcomes.